Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
      • Cryopreservation of allogenic HCT grafts does not adversely impact early post-HCT outcomes
      • Precision medicine initiative uses whole genome sequencing to identify novel prognostic signatures and the impact of genomic subgroups in MDS allogeneic HCT patients
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
      • Advances in HCT Over Time
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Additional Outcomes

  • Unrelated vs. Sibling Donor Outcomes
  • Older Patient Outcomes
  • Timing Impact on Outcomes
Research Spotlight
  • Study results indicate MUDs may be preferred over haplo donors in certain indications

    August 2021

  • Study shows mismatched unrelated donor (MMUD) HCT using PTCY and bone marrow is safe and effective

    April 2021

  • COVID-19 did not impact unrelated donor product delivery for HCT

    January 2021

  • Transplant Indications and Outcomes
  • Additional Outcomes
  • Unrelated vs. Sibling Donor Outcomes
  • Email
  • Print This Page

Related Resources

  • HCT Cell Sources
  • All Outcomes and Statistics Slides

    Patient Resources

    • Transplant Outcomes and Treatment Decisions
    • Transplant Basics Booklet
    • Transplant Basics Videos

      Unrelated vs. Sibling Donor Outcomes

      Due to several clinical advances, such as more precise HLA typing and advances in patient care, unrelated donor transplant outcomes are now comparable to related donor transplant outcomes in many patient populations. [1,2,3,4,5]

      The continued improvement in outcomes has led to an increase in the number of unrelated donor transplants. In 2021, Be The Match® facilitated 6,287 transplants.

      Advances

      Figure 2 shows landmark one-year survival for a rolling cohort of patients consisting of the specified three-year periods. [6] The data show that one-year transplant outcomes for U.S. patients (all diseases, ages and graft types) with unrelated donors have improved 10 percentage points between transplant periods ending in 2005 and in 2010.

      Figure 2. One-Year Survival, NMDP/Be The Match Transplants

      Improved One-Year Survival, Unrelated Donor HCT

      Download Slide: Improved One-Year Survival, Unrelated Donor Transplants

      Advances in treating post-transplant complications and more precise HLA matching have contributed to the improvements in survival. [7,8,9] Unrelated donor transplant outcomes are now comparable to related donor transplant outcomes in several patient populations. [1,2,3,4,5]

      Due to the increased size and ethnic diversity of the Be The Match Registry® and other donor registries, most patients lacking a suitably matched related donor will be able to find an alternative donor and proceed to transplant.

      References

      1. Mielcarek M, Storer BE, Sandmaier BM, et al. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant. 2007; 13(12): 1499-1507. Access
      2. Ho VT, Kim HT, Aldridge J, et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17(8): 1196-1204. Access
      3. Saber W, Opie S, Rizzo JD, et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012; 119(17): 3908-3916. Access
      4. Robin M, Porcher R, Adès L, et al. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS. Bone Marrow Transplant. 2013; 48(10): 1296-1301. Access
      5. Zhang MJ, Davies SM, Camitta BM, et al. Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012; 18(8): 1204-1210. Access
      6. CIBMTR Analysis of NMDP Facilitated Transplants 2013. Unadjusted one-year survival of unrelated transplant recipients after first allogeneic transplantation at U.S. transplant centers.
      7. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13): 4576-4583. Access
      8. Spellman S, Setterholm M, Maiers M, et al. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplant. 2008; 14(9, Suppl. 3): 37-44. Access
      9. Petersdorf EW, Gooley T, Malkki M, Horowitz M. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens. 2007; 69(Suppl. 1): 25-30. Access
      • Email
      • Print This Page

      Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

      Transplant Indications and Outcomes

      • Disease-Specific Indications and Outcomes
      • Additional Outcomes
      • Eligibility
      • Referral Timing Guidelines
      • HLA Today

      Transplant Therapy and Donor Matching

      • Cell Sources
      • HLA Typing and Matching
      • Donor or Cord Blood Search Process
      • Jason Carter Clinical Trials Program

      Resources and Education

      • HCT Presentation Slides
      • Patient Resources
      • Financial Resources
      • Materials Catalog
      • Obstetrician Resources
      • Education Catalog
      • Technique Video
      • Umbilical Cord Blood Collection Training for Public Donation

      Contact Us

      About Us

      Our Websites

      bethematch.org
      BeTheMatch.org Information and support for patients, donors and supporters of our mission.
      BeTheMatchBioTherapies.com
      BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
      CIBMTR.org
      CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
      National Marrow Donor Program —
      Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
      Copyright © 1996-2022 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright